公开(公告)号：NZ579911A

公开(公告)日：2012-05-25

申请号：NZ57991108

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: C07D473/34 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  C07D253/06 ,  C07D487/04

Abstract: Disclosed are irreversible tyrosine kinase inhibitor compounds of Formula (I) (1H-pyrazolo[3,4-d] pyrimidine), wherein the substituents are as described within the specification. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), and the use of a compound of Formula (I) for the manufacture of a medicament for the treatment of an autoimmune disorder, a heteroimmune disorder, inflammation, rheumatoid arthritis, lupus, allergies, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, atopic dermatitis, B-cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or a combination thereof.

公开(公告)号：MX2011000661A

公开(公告)日：2011-05-25

申请号：MX2011000661

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID

IPC: A61K31/52 ,  A61P35/00

Abstract: Descritos en la presente, son compuestos inhibidores de Btk irreversibles, y métodos para el uso de dichos inhibidores irreversibles, en el tratamiento de enfermedades y trastornos caracterizados por la presencia o el desarrollo de tumores sólidos.

公开(公告)号：AU2009270856A8

公开(公告)日：2011-03-03

申请号：AU2009270856

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  CHEN WEI ,  BUGGY JOSEPH ,  LOURY DAVID ,  VERNER ERIK

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：CA2730930A1

公开(公告)日：2010-01-21

申请号：CA2730930

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：CA2874756C

公开(公告)日：2018-05-29

申请号：CA2874756

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C12N9/12 ,  C12Q1/48 ,  G01N33/53

Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

公开(公告)号：MA38183A1

公开(公告)日：2017-03-31

申请号：MA38183

申请日：2013-11-14

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  WANG LONGCHENG

IPC: A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  C07D487/04

Abstract: La présente invention concerne des composés qui forment des liaisons covalentes avec la tyrosine kinase de bruton (btk). L'invention concerne également des inhibiteurs irréversibles de btk. De plus, l'invention concerne également des inhibiteurs réversibles de btk. L'invention concerne également des compositions pharmaceutiques qui comprennent les composés. L'invention concerne des procédés d'utilisation des inhibiteurs de btk, seuls en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies auto-immunes ou d'états auto-immuns, de maladies hétéro-immunes ou d'états hétéro-immuns, le cancer, comprenant un lymphome, et des maladies ou états inflammatoires.

公开(公告)号：BRPI0810086A2

公开(公告)日：2016-07-26

申请号：BRPI0810086

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID ,  VERNER ERIK ,  BUGGY JOSEPH J ,  HONIGBERG LEE ,  CHEN WEI

IPC: A61K31/52 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  C07D253/06 ,  C07D473/34 ,  C07D487/04

公开(公告)号：PE14952015A1

公开(公告)日：2015-10-23

申请号：PE0006252015

申请日：2013-11-14

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  WANG LONGCHENG

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D487/04 ,  A61K31/519

Abstract: Se refiere a compuestos derivados de pirrolopirimidina de formula (I) que son inhibidores de la tirosina quinasa de Bruton (Btk), donde los valores de los sustituyente R1, R6, R7, R8; R24, G, Y, Z y n son los que se definen en la solicitud. Ademas se describen metodos para utilizar los inhibidores Btk, solos o en combinacion con otros agentes terapeuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cancer, incluido el linfoma, y enfermedades o condiciones inflamatorias

公开(公告)号：IN3012DEN2012A

公开(公告)日：2015-07-31

申请号：IN3012DEN2012

申请日：2012-04-09

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: A61K20060101

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

公开(公告)号：CA2890934A1

公开(公告)日：2014-05-22

申请号：CA2890934

申请日：2013-11-14

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  WANG LONGCHENG

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.